| Literature DB >> 30231733 |
Khushbu S Shah1, Upasana Marwah1, Kristina Bundra1, Carol S Goldin2, Michael Toscani1, Joseph A Barone2, John L Colaizzi2.
Abstract
The first dual-degree program combining both the doctor of pharmacy (PharmD) and the doctor of medicine (MD) degrees was designed and launched by Rutgers, The State University of New Jersey, in academic year 2013-2014. This joint effort was led by the Ernest Mario School of Pharmacy (EMSOP) and the Robert Wood Johnson Medical School (RWJMS) to combine expertise in both diagnostic and treatment facets of health care and to prepare graduates for leadership roles in providing and managing comprehensive patient care in a variety of settings. One area of potential value of these skill sets is the drug development industry. A survey was conducted among pharmaceutical executive stakeholders associated with a postdoctoral training program to assess the perceived value of this new dual-degree skill set and to identify particular functions where the combined training has its best fit. Results indicate that the combined nature of this training is highly valued in this setting, especially in the areas of clinical pharmacology, drug safety and pharmacovigilance, medical affairs/strategy, and medical science liaisons. Future monitoring of graduates will further define the value of this dual degree in this and other health care settings.Entities:
Keywords: PharmD/MD; drug development; dual degree; pharma; pharmaceutical industry
Year: 2016 PMID: 30231733 DOI: 10.1177/2168479016652926
Source DB: PubMed Journal: Ther Innov Regul Sci ISSN: 2168-4790 Impact factor: 1.778